Form-20F Publication

RNS Number : 8821E

Hutchison China Meditech Limited

03 March 2020

 

Press release

Publication of Form 20-F

London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ("Chi-Med") (NasdaqAIM: HCM) today published the Form 20-F for the financial year ended December 31, 2019.  This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8821E_1-2020-3-3.pdf and also on the website of the Company at www.chi-med.com .

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President		[phone]
Annie Cheng, Vice President		[phone]
David Dible, Citigate Dewe Rogerson		[phone] (Mobile) [e-mail]
Xuan Yang, Solebury Trout		[phone] (Mobile) [e-mail]
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson		[phone] (Mobile) [e-mail]
Americas - Brad Miles, Solebury Trout		[phone] (Mobile) [e-mail]
Asia	- Joseph Chi Lo, Brunswick	[phone] (Mobile) [e-mail]
	- Zhou Yi, Brunswick	[phone] (Mobile) y [e-mail]
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited		[phone]

 

END

 

 

NRAJJMITMTMMBIM